-Multiple posters being presented on Ascletis’ small molecule and peptide obesity programs<\/i><\/p>\n
-Full analysis of 28-day multiple ascending dose study of oral GLP-1R small molecule agonist ASC30 as a late-breaking poster as well as ASC30 once-monthly treatment formulation and once-quarterly maintenance formulation<\/i><\/p>\n
HONG KONG<\/span><\/span>, Oct. 27, 2025<\/span><\/span> \/PRNewswire\/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces multiple poster presentations of its obesity assets including ASC30, and combination of ASC31 and ASC47 at ObesityWeek\u00ae<\/sup>\u00a02025 in Atlanta, Georgia<\/span>.<\/p>\n Presentation Details: <\/b><\/p>\n Abstract Title:<\/b>\u00a0A full analysis of 28-Day MAD Study of Oral GLP-1R Biased Small Molecule Agonist ASC30 for obesity<\/p>\n Presentation Time:\u00a0<\/b>November 4, 2025<\/span>, 7:30 p.m.-8:30 p.m., EST<\/span><\/p>\n Abstract Title:\u00a0<\/b>ASC30, a Once-Monthly SQ Injected Small Molecule GLP-1RA in Participants with Obesity: A Ph Ib Study<\/p>\n Presentation Time:\u00a0<\/b>November 4, 2025<\/span>, 7:30 p.m.-8:30 p.m., EST<\/span><\/p>\n Abstract Title: <\/b>GLP-1R\/GIPR Peptide Agonist ASC31 + ASC47 Shows 119.6% More Weight Loss than Tirzepatide in DIO Mice<\/p>\n Presentation Time:\u00a0<\/b>November 4, 2025<\/span>, 7:30 p.m.-8:30 p.m., EST<\/span><\/p>\n “We’re excited to present the continued progress of our robust obesity portfolio, including both small molecules and peptides at ObesityWeek\u00ae<\/sup>,” said Jinzi Jason Wu<\/span>, Ph.D., Founder, Chairman and CEO of Ascletis. “These advancements reflect our strong determination to develop highly differentiated options to treat obesity.”<\/p>\n About ASC30<\/b><\/p>\n ASC30 is an investigational GLP-1 receptor (GLP-1R) biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044 without patent extensions.<\/p>\n About ASC31<\/b><\/p>\n ASC31 is an in-house discovered and developed novel peptide agonist targeting both GLP-1R and GIPR, which demonstrated a favorable pharmacokinetic profile in non-human primates as well as promising\u00a0in vitro<\/i>\u00a0activities and\u00a0in vivo<\/i>\u00a0efficacy in the diet-induced obese (DIO) mice. ASC31 is part of Ascletis’ discovery efforts to apply its Ultra-Long-Acting Platform (ULAP) to in-house discovered novel subcutaneously (SQ) injectable peptides and oral peptides.<\/p>\n About ASC47<\/b><\/p>\n ASC47 is an adipose-targeted, once-monthly SQ injected thyroid hormone receptor beta (THR\u03b2) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue.<\/p>\n About ObesityWeek<\/b>\u00ae<\/sup><\/p>\n The preeminent international conference for obesity researchers and clinicians, ObesityWeek\u00ae<\/sup>\u00a0is home to the latest developments in evidence-based obesity science: cutting-edge basic and clinical research, state-of-the-art obesity treatment and prevention, and the latest efforts in advocacy and public policy.\u00a0ObesityWeek\u00ae<\/sup>\u00a02025 will be held from November 4 to 7, 2025<\/span> in Atlanta, Georgia<\/span>.<\/p>\n About Ascletis Pharma Inc.<\/b><\/p>\n Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies, Ascletis has developed multiple drug candidates in-house, including its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).<\/p>\n For more information, please visit www.ascletis.com<\/a>.\u00a0<\/p>\n Contact:\u00a0<\/p>\n Peter Vozzo<\/span> Ascletis Pharma Inc. PR and IR teams <\/p>\n -Multiple posters being presented on Ascletis’ small molecule and peptide obesity programs<\/i><\/p>\n -Full analysis of 28-day multiple ascending dose study of oral GLP-1R small molecule agonist ASC30 as a late-breaking poster as well as ASC30 once-monthly treatment formulation and once-quarterly maintenance formulation<\/i><\/p>\n HONG KONG<\/span><\/span>, Oct. 27, 2025<\/span><\/span> \/PRNewswire\/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces multiple poster presentations of its obesity assets including ASC30, and combination of ASC31 and ASC47 at ObesityWeek\u00ae<\/sup>\u00a02025 in Atlanta, Georgia<\/span>.<\/p>\n Presentation Details: <\/b><\/p>\n Abstract Title:<\/b>\u00a0A full analysis of 28-Day MAD Study of Oral GLP-1R Biased Small Molecule Agonist ASC30 for obesity<\/p>\n Presentation Time:\u00a0<\/b>November 4, 2025<\/span>, 7:30 p.m.-8:30 p.m., EST<\/span><\/p>\n Abstract Title:\u00a0<\/b>ASC30, a Once-Monthly SQ Injected Small Molecule GLP-1RA in Participants with Obesity: A Ph Ib Study<\/p>\n Presentation Time:\u00a0<\/b>November 4, 2025<\/span>, 7:30 p.m.-8:30 p.m., EST<\/span><\/p>\n Abstract Title: <\/b>GLP-1R\/GIPR Peptide Agonist ASC31 + ASC47 Shows 119.6% More Weight Loss than Tirzepatide in DIO Mice<\/p>\n Presentation Time:\u00a0<\/b>November 4, 2025<\/span>, 7:30 p.m.-8:30 p.m., EST<\/span><\/p>\n “We’re excited to present the continued progress of our robust obesity portfolio, including both small molecules and peptides at ObesityWeek\u00ae<\/sup>,” said Jinzi Jason Wu<\/span>, Ph.D., Founder, Chairman and CEO of Ascletis. “These advancements reflect our strong determination to develop highly differentiated options to treat obesity.”<\/p>\n About ASC30<\/b><\/p>\n ASC30 is an investigational GLP-1 receptor (GLP-1R) biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044 without patent extensions.<\/p>\n About ASC31<\/b><\/p>\n ASC31 is an in-house discovered and developed novel peptide agonist targeting both GLP-1R and GIPR, which demonstrated a favorable pharmacokinetic profile in non-human primates as well as promising\u00a0in vitro<\/i>\u00a0activities and\u00a0in vivo<\/i>\u00a0efficacy in the diet-induced obese (DIO) mice. ASC31 is part of Ascletis’ discovery efforts to apply its Ultra-Long-Acting Platform (ULAP) to in-house discovered novel subcutaneously (SQ) injectable peptides and oral peptides.<\/p>\n About ASC47<\/b><\/p>\n ASC47 is an adipose-targeted, once-monthly SQ injected thyroid hormone receptor beta (THR\u03b2) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue.<\/p>\n About ObesityWeek<\/b>\u00ae<\/sup><\/p>\n The preeminent international conference for obesity researchers and clinicians, ObesityWeek\u00ae<\/sup>\u00a0is home to the latest developments in evidence-based obesity science: cutting-edge basic and clinical research, state-of-the-art obesity treatment and prevention, and the latest efforts in advocacy and public policy.\u00a0ObesityWeek\u00ae<\/sup>\u00a02025 will be held from November 4 to 7, 2025<\/span> in Atlanta, Georgia<\/span>.<\/p>\n About Ascletis Pharma Inc.<\/b><\/p>\n Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies, Ascletis has developed multiple drug candidates in-house, including its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).<\/p>\n For more information, please visit www.ascletis.com<\/a>.\u00a0<\/p>\n Contact:\u00a0<\/p>\n Peter Vozzo<\/span> Ascletis Pharma Inc. PR and IR teams <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-37031","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/37031","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37031"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/37031\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37031"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37031"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37031"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com<\/a>\u00a0<\/p>\n
+86-181-0650-9129 (China<\/span>)
pr@ascletis.com<\/a>
ir@ascletis.com<\/a>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com<\/a>\u00a0<\/p>\n
+86-181-0650-9129 (China<\/span>)
pr@ascletis.com<\/a>
ir@ascletis.com<\/a>\u00a0<\/p>\n